Delivering pain relief with peace of mind
Egalet, a fully integrated specialty pharmaceutical company, is focused on developing and commercializing medicines for patients with moderate to severe pain. The company is marketing OXAYDO™ (oxycodone HCl USP) Tablets for oral use only - CII, the first and only approved immediate-release oxycodone product formulated to deter abuse via snorting, for the management of acute and chronic moderate to severe pain where the use of an opioid analgesic is appropriate, and SPRIX® (ketorolac tromethamine) Nasal Spray, a non-steroidal anti-inflammatory drug (NSAID) indicated in adult patients for the short-term (up to 5 days) management of moderate to moderately severe pain that requires analgesia at the opioid level. In addition, using its proprietary Guardian™ Technology, Egalet is developing a pipeline of late-stage opioid-based product candidates that are specifically designed to deter abuse by physical and chemical manipulation. Egalet’s lead programs, Egalet-001, an abuse-deterrent, extended-release, oral morphine formulation, and Egalet-002, an abuse-deterrent, extended-release, oral oxycodone formulation, are in Phase 3 clinical development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate. Egalet’s Guardian Technology platform, which combines abuse-deterrent features and precision delivery, can be applied broadly across different classes of pharmaceutical products and can be used to develop combination products that include multiple active pharmaceutical ingredients with similar or different release profiles.
Learn more about the unmet need for abuse-deterrent opioid analgesics in pain medicine.
OXAYDO is a trademark of Egalet Corporation.
SPRIX is a registered trademark of Egalet Corporation.
Guardian Technology is a trademark of Egalet Corporation.